Innoviva Analyst Price Targets - Benzinga

Innoviva Inc

INVANASDAQ

Trade with Public

Trade with Public

$21.12

0.180.86%

Dern. MÀJ: Oct 28, 4:46 PM

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

Innoviva Analyst Price Targets

Wall Street analyst price targets and consensus rating for Innoviva (INVA).

Price Target Range — 6 Quarters

Analyst Consensus — 5 Analysts

4Buy

1Sell

Consensus RatingBuy# Analysts5Avg. Consensus PT$38Upside to Avg. PT+79.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2026	Oppenheimer	Les Sulewski	Assumes	Outperform	$35
Aug 7, 2026	Cantor Fitzgerald	Steve Seedhouse	PT Cut	Overweight	$36→$34
Jun 22, 2026	BTIG	Julian Harrison	Maintained	Buy	$42
Jun 1, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$46
May 26, 2026	BTIG	Julian Harrison	Maintained	Buy	$42
May 7, 2026	BTIG	Julian Harrison	PT Raise	Buy	$35→$42
Feb 26, 2026	BTIG	Julian Harrison	Maintained	Buy	$35
Feb 17, 2026	BTIG	Julian Harrison	Initiate	Buy	$35
Dec 16, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$45→$46
Nov 6, 2025	Cantor Fitzgerald	Steve Seedhouse	PT Raise	Overweight	$29→$31
Sep 30, 2025	Goldman Sachs	Asad Haider	Initiate	Sell	$17
Aug 11, 2025	Oppenheimer	Trevor Allred	Initiate	Outperform	$35
Aug 11, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$40→$45
Jul 14, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Initiate	Buy	$40
Jul 11, 2025	Cantor Fitzgerald	Steve Seedhouse	Initiate	Overweight	$26
Mar 7, 2025	Scotiabank	Louise Chen	Initiate	Sector Outperform	$55
Aug 1, 2024	Cantor Fitzgerald	Louise Chen	Maintained	Overweight	—
Jul 30, 2024	Cantor Fitzgerald	Louise Chen	Maintained	Overweight	—
Jun 20, 2024	Cantor Fitzgerald	Louise Chen	Maintained	Overweight	—
Jun 18, 2024	Cantor Fitzgerald	Louise Chen	Initiate	Overweight	—

Analyst Ratings News

PRO
Oppenheimer Assumes Innoviva at Outperform, Announces Price Target of $35

Oppenheimer analyst Les Sulewski assumes Innoviva (NASDAQ:INVA) with a Outperform rating and announces Price Target of $35.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on Innoviva, Lowers Price Target to $34

Cantor Fitzgerald analyst Steve Seedhouse maintains Innoviva (NASDAQ:INVA) with a Overweight and lowers the price target from $36 to $34.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Innoviva, Maintains $46 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Innoviva (NASDAQ:INVA) with a Buy and maintains $46 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Innoviva, Maintains $42 Price Target

BTIG analyst Julian Harrison reiterates Innoviva (NASDAQ:INVA) with a Buy and maintains $42 price target.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Innoviva, Raises Price Target to $42

BTIG analyst Julian Harrison maintains Innoviva (NASDAQ:INVA) with a Buy and raises the price target from $35 to $42.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Innoviva, Maintains $35 Price Target

BTIG analyst Julian Harrison reiterates Innoviva (NASDAQ:INVA) with a Buy and maintains $35 price target.

Benzinga Newsdesk